4 Stocks Advancing The Health Services Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 5 points (0.0%) at 16,485 as of Friday, Dec. 27, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,370 issues advancing vs. 1,569 declining with 149 unchanged.

The Health Services industry currently sits down 0.2% versus the S&P 500, which is unchanged. Top gainers within the industry include Intuitive Surgical ( ISRG), up 2.0%, and Express Scripts ( ESRX), up 0.5%. A company within the industry that fell today was Opko Health ( OPK), up 2.4%.

TheStreet would like to highlight 4 stocks pushing the industry higher today:

4. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Services industry higher today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is up $0.18 (0.5%) to $35.40 on light volume. Thus far, 25,533 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 137,500 shares. The stock has ranged in price between $35.40-$35.63 after having opened the day at $35.62 as compared to the previous trading day's close of $35.22.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, operates in the field of dialysis care and dialysis products for the treatment of end-stage renal disease. Fresenius Medical Care AG & Co. KGaA has a market cap of $21.1 billion and is part of the health care sector. Shares are up 2.7% year to date as of the close of trading on Thursday. Currently there are 2 analysts that rate Fresenius Medical Care AG & Co. KGaA a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Grifols ( GRFS) is up $0.19 (0.5%) to $36.05 on light volume. Thus far, 37,413 shares of Grifols exchanged hands as compared to its average daily volume of 569,500 shares. The stock has ranged in price between $35.91-$36.45 after having opened the day at $36.26 as compared to the previous trading day's close of $35.86.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $12.1 billion and is part of the health care sector. Shares are up 38.3% year to date as of the close of trading on Thursday. Currently there are 3 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full Grifols Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Laboratory Corporation of America Holdings ( LH) is up $0.61 (0.7%) to $91.31 on light volume. Thus far, 111,830 shares of Laboratory Corporation of America Holdings exchanged hands as compared to its average daily volume of 949,900 shares. The stock has ranged in price between $91.11-$91.68 after having opened the day at $91.37 as compared to the previous trading day's close of $90.70.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. Laboratory Corporation of America Holdings has a market cap of $8.0 billion and is part of the health care sector. Shares are up 4.7% year to date as of the close of trading on Thursday. Currently there are 3 analysts that rate Laboratory Corporation of America Holdings a buy, 2 analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates Laboratory Corporation of America Holdings as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, revenue growth, notable return on equity, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Laboratory Corporation of America Holdings Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Edwards Life ( EW) is up $0.57 (0.9%) to $65.96 on light volume. Thus far, 277,321 shares of Edwards Life exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $65.13-$65.96 after having opened the day at $65.43 as compared to the previous trading day's close of $65.39.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Life has a market cap of $7.2 billion and is part of the health care sector. Shares are down 27.5% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Edwards Life a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Edwards Life as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Edwards Life Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists